Podcasts

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Navigating Market Access Hurdles

Articles

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

Bora Pharmaceuticals to Purchase Emergent’s Sterile Manufacturing Facility 

A cross-sectional study explores the broader issue of whether racial segregation in local acute care hospitals exists, while focusing on the demographic of older Black patients enrolled in Medicare. 

Do Medicare Hospital Admit a Representative Number of Beneficiaries Based on Their Respective Market Areas?

Videos

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses what to expect from Cardinal Health's biosimilars pipeline. 

Looking Ahead to Cardinal Health's Biosimilar Pipeline

Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.

Ascidian Therapeutics, Roche Enter RNA Exon Editing Therapeutics Collaboration

The deal also adds a spread of supply chain efficiency, sustainability, and patient safety outcomes to the mix.

Sensitech Bolsters Its Cold Chain Offerings, Acquires Berlinger & Co. Monitoring Solutions 

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, explains how digital formats help manufacturers better manage price based on real-time data, along with the impact of NDC-specific price dexterity.

Helping Manufacturers Better Manage Price

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health discusses the growing biosimilars market and the challenges associated with regulation and adoption. 

Cardinal Health VP of Emerging Therapies Talks Regulation and Adoption Challenges for Biosimilars

A cross-sectional study among patients with both cancer and a SARS-CoV-2 infection investigates if there were racial and ethnic disparities in treatment delays or discontinuations.

Differences in Cancer Treatment Continuity Throughout the COVID-19 Pandemic

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

News